Stockreport

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy [Yah...

Scholar Rock Holding Corporation  (SRRK) 
Last scholar rock holding corporation earnings: 11/12 07:30 am Check Earnings Report
PDF FDA to review BLA application under priority review, with a PDUFA date of September 22, 2025 Apitegromab Marketing Authorisation Application to the European Medicines [Read more]